Use of fgfr1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in fgfr2
AssigneeFive Prime Pharmaceutials, Inc.
InventorsThomas Harding, Michael W. Kavanaugh
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253.
Claims13
1-56. (canceled)
A method of treating cancer in a subject comprising:
- a) determining whether cells from the cancer comprise a ligand dependent activating mutation in FGFR2;
- and
- b) if the cells comprise a ligand dependent activating mutation in FGFR2, administering a therapeutically effective amount of an FGFR1 ECD to the subject.
A method of treating cancer in a subject comprising:
- a) having cells from the cancer tested for the presence of a ligand dependent activating mutation in FGFR2;
- and
- b) if the cells comprise a ligand dependent activating mutation in FGFR2, administering a therapeutically effective amount of an FGFR1 ECD to the subject.
A method of treating cancer comprising administering a therapeutically effective amount of an FGFR1 ECD to a subject, wherein the cancer has previously been characterized as having a ligand dependent activating mutation in FGFR2.
Dependencies are inferred from the claim text.